Expression of (pro)renin receptor in breast cancers and its effect on cancer cell proliferation
Expression of (pro)renin receptor in breast cancers and its effect on cancer cell proliferation
复制标题
DOI：
10.2220/biomedres.35.117
复制
发表时间：
2014-04-01
影响因子：
1.2
通讯作者：
Takahashi, Kazuhiro
中科院分区：
文献类型：
--
作者：
Ohba, Koji;Suzuki, Takashi;Takahashi, Kazuhiro
（Pro）肾素受体（(P)RR）是肾素和原肾素的特异性受体。本研究旨在阐明(P)RR的表达及其在人乳腺癌中的病理生理作用。(P)应用免疫组织化学方法对69例乳腺癌患者的RR表达进行了研究。用(P)RR特异性小干扰RNA检测(P)RR对培养的人乳腺癌细胞增殖的影响。免疫组化结果显示，69例乳腺癌中有50例（72%）乳腺癌细胞检测到(P)RR免疫反应性。(P)RR免疫反应性与临床病理参数的相关性分析显示，Ki-67（细胞增殖标志物）>= 10%组(P)RR阳性病例数显著高于Ki-67 < 10%组（P = 0.02）。(P)RR在4种人乳腺癌细胞系中均有表达。(P)RR特异性小干扰RNA抑制MCF-7 （ER α阳性）和SK-BR-3 （ERa，阴性）细胞的增殖。本研究首次发现(P)RR在人乳腺癌组织和培养的乳腺癌细胞系中的表达。这些发现提出了一种可能性，即阻断(P)RR信号可能是一种新的治疗乳腺癌的策略。
(Pro)renin receptor ((P)RR) is a specific receptor for renin and prorenin. The aim of the present study is to clarify expression of (P)RR and pathophysiological roles of (P)RR in human breast carcinomas. (P)RR expression was studied in 69 clinical cases of breast carcinoma by immunohistochemistry. Effects of (P)RR on cell proliferation were examined in cultured human breast carcinoma cells using (P)RR specific small interference RNA. Immunohistochemistry showed that (P)RR immunoreactivity was detected in the breast carcinoma cells in 50 of 69 cases of breast carcinoma (72%). The analysis on association between (P)RR immunoreactivity and clinicopathological parameters showed that the number of (P)RR positive cases was significantly greater in Ki-67 (a cell proliferation marker) >= 10% group than in Ki-67 < 10% group (P = 0.02). (P)RR was expressed in 4 types of human breast carcinoma cell lines. (P)RR specific small interference RNA inhibited proliferation of both MCF-7 (ER alpha positive) and SK-BR-3 (ERa, negative) cells. The present study has shown, for the first time, the expression of (P)RR in human breast carcinoma tissues and cultured breast carcinoma cell lines. These findings have raised the possibility that the blockade of the (P)RR signaling may be a novel therapeutic strategy against breast carcinomas.